Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                Drug Shortages

Drug Shortages

                        Drug Shortages | Additional News and Information
          Frequently Asked Questions about Drug Shortages
          Drug Shortages Infographic Home
          Drugs
          Drug Safety and Availability
          Drug Shortages
          Report | Drug Shortages: Root Causes and Potential SolutionsDrug Shortages Report | Drug Shortages: Root Causes and Potential Solutions
  
  	
    Share
    Post
    Linkedin

    Email
    Print*Drug Shortages: Root Causes and Potential Solutions,* published in October 2019, examines the underlying factors responsible for drug shortages and recommends enduring solutions. The inter-agency Drug Shortage Task Force, which was led by FDA, oversaw the analysis of drug shortage data and development of recommendations in response to a request from 31 U.S. senators and 104 U.S. congressional representatives in June 2018.

The recommendations were based on insights gleaned from public and private stakeholders at a November 2018 Drug Shortages Task Force Public Meeting, a docket for comments, and listening sessions with stakeholders, as well as FDA data analysis and published research.

The report identifies three root causes for drug shortages:

Lack of incentives for manufacturers to produce less profitable drugs;
	The market does not recognize and reward manufacturers for “mature quality systems” that focus on continuous improvement and early detection of supply chain issues; and
	Logistical and regulatory challenges make it difficult for the market to recover from a disruption.The report also recommends enduring solutions:

Creating a shared understanding of the impact of drug shortages on patients and the contracting practices that may contribute to shortages;
	Developing a rating system to incentivize drug manufacturers to invest in quality management maturity for their facilities; and
	Promoting sustainable private sector contracts (e.g., with payers, purchasers, and group purchasing organizations) to make sure there is a reliable supply of medically important drugs.In addition, the report describes legislative proposals in the President’s FY2020 Budget and planned FDA initiatives to prevent and mitigate shortages that look at improved data sharing, risk management, lengthened expiration dates for drugs, and internationally harmonized guidelines for a pharmaceutical quality system.

In February 2020, FDA recalculated both the production increase and the extent of supply restoration for drugs that were in shortage between 2013 and 2017.  To do so, the Agency used new approaches that better capture whether each drug became more readily available during the shortage. FDA found that 42 percent of the shortage drugs had a significant production increase, meaning that new suppliers entered the market and/or existing suppliers increased their output to an extent that restored at least half of the quantity of the drug that was unavailable during the shortage.  Similarly, the Agency found that 30 percent of the shortage drugs had their quantity fully restored to pre-shortage levels.  The changes do not affect the Report’s conclusions or recommendations.

The revised text is in two sections:

Evidence for Root Causes, Events that Happen After Occurrence of a Shortage on pages 36 - 37; and
	Appendix F, Key Findings, Key Finding 3 on pages 119 - 121.**Executive Summary**

(PDF - 821 KB)




**Full Report**

(Oct. 2019 Report, Updated Feb. 2020, PDF - 3.9 MB)

                                                                                  Content current as of:
      03/11/2020
              
              
Regulated Product(s)
		 DrugsDrug Shortages

          
                        Drug Shortages | Additional News and Information
          Frequently Asked Questions about Drug Shortages
          Drug Shortages Infographic
 
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop